| Tuesday | ||||
Biocept announces that it… Biocept announces that it has been awarded Canadian Patent 2812291, entitled "METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION." This patent covers methods for enhancing the detection of cells using fluorescent complexes, including circulating tumor cells and from a biological fluid. The issuance of this patent increases Biocept's total patent awards for use in its molecular diagnostics business to 40. | ||||
| Over a week ago | ||||
Biocept announces it has… Biocept announces it has entered into a managed care provider agreement with Medical Cost Containment Professionals to process out-of-network claims for Biocept's Target Selector liquid biopsy testing. MCCP is a reference-based pricing insurance network that includes more than 150,000 providers nationwide. | ||||
Biocept announces the… Biocept announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for SAR-CoV-2 for physician ordering. Collected specimens will be shipped overnight to Biocept's high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego with results returned to ordering physicians in an estimated 24 to 48 hours. | ||||
Biocept announces that it… Biocept announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. The move is expected to be completed by 2020 year end. The company's new 39,000-square-foot headquarters, manufacturing and lab facility will be located at 9955 Mesa Rim Road, San Diego, CA 92121. | ||||
| Over a month ago | ||||
Maxim Group Virtual… Maxim Group Virtual COVID-19 Conference will be held on May 27. | ||||
Brookline analyst Sally… Brookline analyst Sally Yanchus initiated coverage of Biocept with a Buy rating and $2.06 price target. | |
Biocept announces the… Biocept announces the award of CE, or Conformite Europeene,-IVD Mark for its Target Selector molecular assay EGFR Kit. The CE Mark confirms that the Company's Target Selector(TM) kit products meet the requirements of the European In-Vitro Diagnostic Devices Directive and allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies. Biocept's Target Selector molecular assay kits detect key oncogene mutations through the analysis of both Formalin-Fixed Paraffin-Embedded tissue gained from surgical biopsies as well as circulating tumor DNA gained from blood-based liquid biopsies. | |
The registered direct… The registered direct offering priced below the last closing price of $0.60. Maxim is acting as sole book running manager for the offering. | |
Biocept announces that it… Biocept announces that it has verified a COVID-19 molecular diagnostic test, and plans to begin accepting physician-ordered testing requests for processing beginning on April 15, 2020. Biocept has partnered with a national clinician network to accept patient samples and may obtain additional agreements as test capacity is increased. Biocept operates a high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego, with specialized, licensed molecular lab staff that have been trained in performing the COVID-19 testing. The lab will be using the FDA-approved for EUA testing ThermoFisher Scientific's TaqPath molecular diagnostic platform and kit for SARS-CoV-2. |